Posted on April 1, 2016 by Sitemaster
A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, castration-resistant, CRPC, everolimus, outcome, trial | 1 Comment »
Posted on October 5, 2015 by Sitemaster
There is an increasing level of evidence about our ability to identify small and carefully selected groups of patients with advanced disease who, despite the fact that they no longer respond to standard treatments, may respond well to other forms of therapy. … READ MORE …
Filed under: Uncategorized | Tagged: carboplatin, castration-resistant, chemotherapy, everolimus, individualized, metastatic, outcome, personalized | 5 Comments »
